Els Goetghebeur
Affiliations: | Applied Mathematics | Grent University |
Area:
Biostatistics, Causal inference, Quality of care, Survival analysisWebsite:
https://ai.ugent.be/people/ElsGoetghebeur.en.htmlGoogle:
"Els Goetghebeur"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Ciocănea-Teodorescu I, Goetghebeur E, Waernbaum I, et al. (2023) Causal inference in survival analysis under deterministic missingness of confounders in register data. Statistics in Medicine |
Ost P, Reynders D, Decaestecker K, et al. (2020) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. Journal of Clinical Oncology. 38: 10-10 |
Bruycker AD, Spiessens A, Dirix P, et al. (2020) PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial. Bmc Cancer. 20: 406 |
Sundahl N, Vandekerkhove G, Decaestecker K, et al. (2019) Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. European Urology. 75: 707-711 |
Vandekerkhove G, Sundahl N, Decaestecker K, et al. (2019) Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results. Journal of Clinical Oncology. 37: 422-422 |
Ost P, Sundahl N, Vandekerkhove G, et al. (2019) Randomized phase 1 trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results European Urology Supplements. 18 |
Sundahl N, De Wolf K, Kruse V, et al. (2018) Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma. International Journal of Radiation Oncology, Biology, Physics. 100: 906-915 |
Sundahl N, Rottey S, Decaestecker K, et al. (2018) OC-0682: Phase 1 trial of pembrolizumab with SBRT in metastatic urothelial carcinoma Radiotherapy and Oncology. 127 |
Ost P, Reynders D, Decaestecker K, et al. (2017) Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017754853 |
Sundahl N, De Wolf K, Rottey S, et al. (2017) A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. Journal of Translational Medicine. 15: 150 |